Vertex is pleased to confirm that a funding application for Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) has been made to PHARMAC. This follows our recent submission earlier in June to Medsafe for the evaluation of Trikafta for the treatment of cystic fibrosis ...
